Mobile site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

STAY UP TO DATE

Sign up to get news about TAKHZYRO as it becomes available, as well as information about hereditary angioedema (HAE).

All fields are required unless otherwise noted.

Specialty

By providing your information, you consent to receiving marketing and promotional communications and other information from Takeda. You hereby give consent to Takeda, its affiliates, and their agents and representatives to send communications and information to you via the contact information you have provided above. This consent will be in effect until such time as you opt out of communications from Takeda. If, at any time, you no longer wish to receive communications from Takeda, you can opt out by calling 1-877-TAKEDA-7 (1-877-825-3327). Please see our privacy policy.